SCHEMBL3522685

SCHEMBL3522685

CCOC(=O)CNC(=O)c1c(O)cc(Br)c2nccnc12

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.44
HPGD P15428 4/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
ALDH1A1 P00352 5/20 0.42
MAPT P10636 1/20 0.42
HSD17B10 Q99714 3/20 0.41
LMNA P02545 2/20 0.41
NPC1 O15118 3/20 0.39
RAB9A P51151 3/20 0.39
CASP1 P29466 2/20 0.39
KDM4E B2RXH2 2/20 0.39
TP53 P04637 1/20 0.39
GLA P06280 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.37
CASP7 P55210 1/20 0.37
NPSR1 Q6W5P4 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3520599 0.82 FTO (0.48)
SCHEMBL3521107 0.81 EGLN3 (0.44) GAAHPGDSMN1; SMN2ALDH1A1MAPT
SCHEMBL3516693 0.81 HPGD (0.49) GAAHPGDSMN1; SMN2ALDH1A1HSD17B10
SCHEMBL3516100 0.72 HPGD (0.43) GAAHPGDSMN1; SMN2ALDH1A1MAPT
SCHEMBL3761040 0.72 HPGD (0.45) GAAHPGDSMN1; SMN2ALDH1A1MAPT
SCHEMBL3756337 0.72 EGLN3 (0.43) GAAHPGDSMN1; SMN2ALDH1A1MAPT
SCHEMBL3521075 0.71 EGLN3 (0.52) GAAHPGDSMN1; SMN2ALDH1A1MAPT
SCHEMBL25934739 0.70 EGLN2 (0.65) HPGDSMN1; SMN2ALDH1A1HSD17B10LMNA
SCHEMBL3521029 0.70 EGLN3 (0.48) GAAHPGDSMN1; SMN2ALDH1A1MAPT
SCHEMBL3524111 0.70 EGLN3 (0.46) GAAHPGDSMN1; SMN2ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101983384-A Prolyl hydroxylase inhibitors SMITHKLINE BEECHAM CORP 2011-03-02 CN disclosed
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
EP-2227770-A2 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-15 EP disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305133-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 GAA 142/4885HPGD 51/4885SMN1; SMN2 3777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.